西兰司琼联合双歧杆菌三联活菌治疗肠易激综合征的疗效

Curative efficacy of cilansetron combined with bifidobacterium triad in the treatment of irritable bowel syndrome

目的探讨西兰司琼联合双歧杆菌三联活菌治疗肠易激综合征的疗效。方法选择2015年11月至2017年11月我院接诊的96例肠易激综合征患者作为研究对象,通过随机数表法分为观察组(48例)和对照组(48例),在常规治疗基础上,对照组使用双歧杆菌三联活菌治疗,观察组联合西兰司琼治疗,两组均连续治疗6 d。比较两组临床疗效、血清白介素(IL)-6、IL-8、IL-10、5-羟色胺(5-HT)及临床症状积分的变化。结果治疗后,观察组临床总有效率为91.67%(44/48),明显高于对照组的72.92%(35/48)(P <0.05);治疗后,两组血清IL-6、IL-8较治疗前均显著降低,IL-10显著升高(P <0.05),且观察组血清IL-6、IL-8均明显低于对照组[(8.45±1.40) vs.(11.94±1.82) ng/L,(1.34±0.25) vs.(2.61±0.33) ng/L,P <0.05],IL-10明显高于对照组[(36.68±5.34) vs.(24.75±4.10) ng/L,P <0.05];治疗后,两组血清5-HT较治疗前均显著降低(P <0.05),观察组血清5-HT明显低于对照组[(84.23±15.92) vs.(102.12±18.45) ng/ml,P <0.05)];治疗后,两组腹泻、腹痛、恶心呕吐症状积分较治疗前均显著降低(P <0.05),观察组腹泻、腹痛、恶心呕吐症状积分均明显低于对照组[(0.75±0.13) vs.(1.11±0.17)分,(0.66±0.11) vs.(0.92±0.14)分,(0.59±0.10) vs.(0.75±0.13)分,P <0.05];两组治疗期间均未出现明显不良反应。结论在肠易激综合征患者中使用西兰司琼联合双歧杆菌三联活菌效果显著,可有效调节血清炎性因子表达、促进临床症状缓解,且用药安全,值得应用推广。

Objective To study the curative efficacy of cilansetron combined with bifidobacterium triad in the treatment of irritable bowel syndrome. Methods Totally 96 patients with irritable bowel syndrome who received treat- ment from November 2015 to November 2017 in our hospital were selected as research objects,and according to random number table ,those patients were divided into observation group （n =48 ） and control group （n=48 ）. On the basis of routine treatment ,both groups were treated with bifidobacterium triad, and the observation group was added cilansetron ; they were treated continuously with 6 d. The clinical efficacy, the changes of serum interleukins （IL） 45, IL-8, IL-10,5- hydroxytryptamine （5-HT） and clinical symptom scores were compared between the two groups. Results After treatment, the total effective rate in observation group was 91.67% （44/48）, which was significantly higher than that of control group （72.92% ,35/48）（P 〈0. 05） ; the serum IL45 and IL-8 in the two groups were decreased,and the IL-10 significantly increased （ P 〈 0. 05 ）, and the serum IL-6 and IL-8 in observation group were lower than those of control group [ （ 8.45 ± 1.40） vs. （ 11.94 ±1.82 ） ng/L, （ 1.34 ±0. 25 ） vs. （2. 61 ±0. 33 ） ng/L,P 〈 0. 05] , while the IL-10 in observation group was higher E （ 36. 68 ±5.34 ） vs. （ 24. 75 ±4. 10 ） ng/L, P 〈 0. 05 ] ; the serum 5-HT in the two groups was decreased（P 〈0. 05） ,and the serum 5-HT in observation group was lower than that of control group [ （84. 23 ±15. 92） vs. （102. 12 ±18.45 ）ng/ml ,P 〈 0. 05 ] ;the clinical symptom scores of diarrhea, abdominal pain and nausea and vomiting in the two groups were decreased（P 〈 0. 05 ） , and these scores in observation group were lower than those of control group [ （0. 75 ±0. 13） vs. （1.11 ±0. 17） ,（0. 66 ±0. 11） vs. （0.92 ±0. 14）, （0.59 ±0. 10） vs. （0.75 ±0. 13）,P 〈0. 05]. No significant adverse reaction was observed in the two groups. Conclusion Cilansetron combined with bifidobacterium triad is significantly effective for irritable bowel syndrome, which can effectively regulate the expression of serum inflammatory factors and promote the remission of clinical symptoms, and it is safe and worthy of application.